The rationale and use of topiramate for treating neuropathic pain

Clinical Journal of Pain

Volumn 19, Issue 1, 2003, Pages 59-68

  Chong, M S ^a,b   Libretto, Susan E ^c  

^a MEDWAY MARITIME HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c Janssen Cilag Ltd   (United Kingdom)

Author keywords

Neuropathic pain; Topiramate; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; AMPA RECEPTOR ANTAGONIST; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; FLUMAZENIL; KAINIC ACID RECEPTOR ANTAGONIST; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; TOPIRAMATE;

ARTICLE; CLINICAL FEATURE; DIABETIC NEUROPATHY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG RECEPTOR BINDING; ELECTRIC POTENTIAL; HUMAN; INTERCOSTAL NERVE; NEUROPATHIC PAIN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TRIGEMINUS NEURALGIA; WEIGHT REDUCTION;

ANALGESICS; ANIMALS; CARBONIC ANHYDRASES; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EVALUATION STUDIES; FRUCTOSE; HUMANS; HYPERALGESIA; ION CHANNELS; NEURALGIA; RECEPTORS, GABA; RECEPTORS, GLUTAMATE; SYNAPTIC TRANSMISSION;

EID: 0037220090     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002508-200301000-00008     Document Type: Article

References (63)

1. Patsalos PN. The pharmacokinetic pharmacokinedc profile of topiramate. Rev Contemp Pharmacother 1999;10:155-62.
2. Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of Topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurones. Epilepsia 1993;34:44-5.
3. Severt L, Coulter DA, Sombati S, et al. Topiramate selectively blocks kainate currents in cultured hippocampal neurones. Epilepsia 1995;36:38.
4. Avoli M, Kawasaki H, Zona C. Effects induced by topiramate on sodium electrogenesis in mammalian central neurones. Epilepsia 1996;37:51-2.
5. Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 1997; 231:123-6.
6. Kawasaki H, Tancredi V, D'Arcangelo G, et al. Multiple actions of the novel anticonvulsant topiramate in the rat subiculum in vitro. Brain Res 1998;807:125-34.
7. Avoli M, Lopantsev V. Topiramate blocks ictal-like discharges in the entorhinal cortex: B.04. Epilepsia 1997;38:44-5.
8. Taverna S, Sancini G, Nantegazza M, et al. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther 1999;288:960-8.
9. Wu SP, Tsai JJ, Gean PW. Frequency-dependent inhibition in neuronal activity by topiramate in rat hippocampal slices. Br J Pharmacol 1998;125:826-32.
10. Brown SD, Wolf HH, Swinyard UA, et al. The novel anticonvulsant topiramate enhancers GABA-mediated chloride flux. Epilepsia 1993;34:122.
11. White HS, Brown SD, Woodhead JH, et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurones and increases seizure threshold. Epilepsy Res 1997;28:167-79.
12. White HS, Brown D, Skeen GA, et al. The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride currents. Epilepsia 1995;36(Suppl):S39.
13. White HS, Brown SD, Woodhead JH, et al. Topiramate modulates GABA-evoked currents in murine cortical neurones by a nonbenzodiazapine mechanism. Epilepsia 2000;41(Suppl):S17-S20.
14. Zhang XL, Velumian AA, Jones OT, et al. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000;41(Suppl):S52-S60.
15. Sombati S, Coulter DA, DeLorenzo RJ. Effects of topiramate on sustained repetitive firing and low Mg2+-induced seizure discharges in cultured hippocampal neurones. Epilepsia 1995;36:38.
16. Coulter DA, Sombati S, DeLorenzo RJ. Topiramate's effects on excitatory amino acid-mediated responses in cultured hippocampal neurones: Selective blockade of kainate currents. Epilepsia 1995;36(Suppl):S40.
17. Gibbs JW III, Sombati S, DeLorenzo RJ, et al. Cellular actions of topiramate: Blockade of kainate-evoked inward currents in cultured hippocampal neurones. Epilepsia 2000;41(Suppl):S10-S16.
18. Kanda T, Nakamura J, Kurokawa M, et al, Inhibition of excessive releases of excitatory amino acids in hippocampus of spontaneous epileptic rat (SER) by topiramate (KW-6485). Jap J Pharmacol 1992;58:92.
19. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000;41(Suppl):S35-9.
20. Kanda T, Kurokawa M, Tamura S, et al. Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER). Life Sci 1996; 59:1607-16.
21. Staley KJ, Soldo BL, Proctor WR. Ionic mechanisms of neuronal excitation by inhibitory GABAA receptors. Science 1995;269: 977-81.
22. Merskey H, Bogduk N, eds. Classification of Chronic Pain, 2nd Ed. Seattle: IASP Press, 1994.
23. Bowsher D. Neurogenic pain syndromes and their management. Br Med Bull 1991;47:644-66.
24. Woolf CJ, Mannion RJ. Neuropathic pain: Etiology, symptoms, mechanisms, and management. Lancet 1999;353:1959-64.
25. IASP. New directions in neuropathic pain: Focusing treatment on symptoms and mechanisms. IASP Newslett 1999;2-32.
26. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 2000;288:1765-9.
27. Woolf CJ. Generation of acute pain: Central mechanisms. Br Med Bull 1991;47:523-33.
28. Thompson SWN, King AE, Woolf CJ. Activity-dependent changes in rat ventral horn neurones in vitro: Summation of prolonged postsynaptic depolarization produces a D-APV sensitive windup. Eur J Neurosci 1990;2:638-49.
29. Torebjörk HE, Lundberg LE, LaMotte RH. Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperaigesia in humans. J Physiol 1992;448:765-80.
30. Koltzenburg M, Torebjork HE, Wahren LK. Nociceptor modulated central sensitisation causes mechanical hyperalgesia in acute chemogenic and chronic neuropathic pain. Brain 1994;117:579-91.
31. Rang HP, Urban L. New molecules in analgesia. Br J Anaesth 1995;75:145-56.
32. Brennan T. AMPA/Kainate receptor antagonist as novel analgesic agents. Anesthesiology 1998;89:1049-51.
33. Sang CN, Hostetter MP, Graceley RH, et al. AMPA/Kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 1998;89:1060-7.
34. Conti F, Weinberg RJ. Shaping excitation at glutaminergic synapses. TINS 1999;451-8.
35. Dickenson AH, Chapman V, Green GM. The pharmacology of excitatory and inhibitory amino acids-mediated events in the transmission and modulation of pain in the spinal cord. Gen Pharmacol 1997;28:633-8.
36. Dickenson AH. Spinal cord pharmacology of pain. Br J Anaesth 1995;75:193-200.
37. 2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 1992;356:521-3.
38. Graceley RH, Lynch SA, Bennet GJ. Painful neuropathy: Altered central processing maintained dynamically by peripheral input. Pain 1992;51:175-94.
39. Woolf CJ, Doubell TP. The pathophysiology of chronic pain-increased sensitivity to low threshold Aβ-fiber inputs. Curr Opin Neurobiol 1994;4:525-34.
40. Sawynok Y. GABAergic mechanism of analgesia: An update. Pharmacol Biochem Behav 1987;26:463-74.
41. Malcangio M, Bowery N. γ-Aminobutyric acid B but not γ-aminobutyric acid A receptor activation inhibits electrically evoked substance-P-like immunoreactivity from rat spinal cord in vivo. J Pharmacol Exp Ther 1993;266:1490-6.
42. Suh HW, Kim YH, Choi YS, et al. Effects of GABA receptor antagonists injected spinally on antinociception induced by opioids administered supraspinally in mice. Eur J Pharmacol 1996;307: 141-7.
43. Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers sprouting of myelinated afferents. Nature 1992;355:75-7.
44. Novakovic SD, Tzoumaka E, McGivern JG, et al. Distribution of the tetrodotoxin-resistant sodium channel, PN3, in rat sensory neurons in normal and neuropathic conditions. J Neurosci 1998;18: 2174-87.
45. Dib-Hajj SD, Fjell J, Cummins TR, et al. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 1999;83:591-600.
46. Bowersox SS, Gadbois T, Singh T, et al. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J Pharmacol Exp Ther 1996;279:1243-9.
47. Goucke CR, Mathur V, Luther R. The complex patient with opioid resistant chronic pain: the analgesic effect of intrathecal ziconitide. International Association for the Study of Pain 9th World Congress on Pain. Vienna, 1999:446;236 (abstract).
48. Santillan R, Maestre JM, Hurle MA, et al. Nimodipine-enhanced opiate analgesia in cancer patients requiring morphine dose escalation: A double-blind placebo controlled study. Pain 1998;76: 17-26.
49. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50:355-63.
50. Shadiack AM, Molino LJ, Yagel SK, et al. The novel anticonvulsant topiramate is anti-allodynic in a rat model of neuropathic pain. Analgesia 1999;4:173-9.
51. Wild KD, Yagel SK, Shank RP. The novel anticonvulsant topiramate is anti-allodynic in a rat model of neuropathic pain. Soc Neurosci Abstr 1997;23:2358 (abstract 918.10).
52. Timberlake CM, Chong S, Fung M, et al. Open label study of topiramate, a novel antiepileptic, in neuropathic pain. International Association for the Study of Pain 9th World Congress on Pain. Vienna, 1999:446;236 (abstract).
53. Edwards KR, Glantz MJ. An evaluation of topiramate in the management of painful diabetic neuropathy. Presented at the 17th Annual Science Meeting of the American Pain Society, San Diego, CA, November 5-8, 1998 (poster, abstract).
54. Edwards KR, Glanz MJ, Button J, et al. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Neurology 2000;54:A81.
55. Topamax fails in diabetic neuropathy. Scrip Sep 21 2001;2680:23.
56. Bajwa ZH, Sami N, Warfield CA, et al. Topiramate relieves refractory intercostal neuralgia. Neurology 1999;52:1917.
57. Zvartau-Hind M, Din MU, Gilani A, et al. Topiramate relieves refractory trigeminal neuralgia in multiple sclerosis patients. Neurology 2000;55:1587-8.
58. Haugh MJ, Connor GS. Trigeminal neuralgia: Pain relief in patients treated with the anticonvulsant topiramate. Presented at a meeting of the American Pain Society, Atlanta, GA, November 2-5, 2000 (poster).
59. Gilron I, Booher SL, Rowan JS, et al. Topiramate in trigeminal neuralgia: A randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol 2001;24:109-12.
60. Solaro C, Uccelli MM, Brichetto G, et al. Topiramate relieves idiopathic and symptomatic trigeminal neuralgia. J Pain Symptom Manage 2001;21:367-8.
61. Potter D, Edwards KR. Potential role of topiramate in relief of neuropathic pain. Neurology 1998;50:A255.
62. Pappagallo M. Preliminary experience with topiramate in the treatment of chronic pain syndromes. Presented at the 17th Annual Science Meeting of the American Pain Society, San Diego, CA, November 5-8, 1998 (poster).
63. Connor GS. Efficacy of the antiepileptic topiramate in treatment-resistant diabetic or idiopathic neuropathy. Presented at a meeting of the American Pain Society. Atlanta, GA, November 2-5, 2000 (poster).